Jean-Jacques Bienaimé net worth and biography

Jean-Jacques Bienaimé Biography and Net Worth

Director of Keros Therapeutics

Jean-Jacques Bienaimé has served as a member of our board of directors since June 2024, served as Lead Independent Director of our board of directors from July 2024 to August 2025, and has served as Chair of our board of directors since August 2025. Mr. Bienaimé was most recently the Chief Executive Officer and Chairman of BioMarin Pharmaceutical Inc. Previously, Mr. Bienaimé served as the Chairman, Chief Executive Officer and President of Genencor, Inc. Prior to Genencor, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation. Mr. Bienaimé also held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. Mr. Bienaimé currently serves on the board of directors of Ascendis Pharma A/S, Incyte Corporation and Immunome, Inc., as well as serving on the board of directors of a private biotechnology company. Mr. Bienaimé received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris.

What is Jean-Jacques Bienaimé's net worth?: The estimated net worth of Jean-Jacques Bienaimé is at least $187.97 thousand as of June 15th, 2026. Mr. Bienaimé owns 17,592 shares of Keros Therapeutics stock worth more than $187,971 as of July 17th. This net worth evaluation does not reflect any other assets that Mr. Bienaimé may own. Learn More about Jean-Jacques Bienaimé's net worth.
How do I contact Jean-Jacques Bienaimé?: The corporate mailing address for Mr. Bienaimé and other Keros Therapeutics executives is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. Keros Therapeutics can also be reached via phone at 617-314-6297 and via email at [email protected]. Learn More on Jean-Jacques Bienaimé's contact information.
Has Jean-Jacques Bienaimé been buying or selling shares of Keros Therapeutics?: Jean-Jacques Bienaimé has not been actively trading shares of Keros Therapeutics within the last three months. Most recently, on Monday, June 15th, Jean Jacques Bienaime bought 1,000 shares of Keros Therapeutics stock. The stock was acquired at an average cost of $10.19 per share, with a total value of $10,190.00. Following the completion of the transaction, the director now directly owns 17,592 shares of the company's stock, valued at $179,262.48. Learn More on Jean-Jacques Bienaimé's trading history.
Who are Keros Therapeutics' active insiders?: Keros Therapeutics' insider roster includes Jean-Jacques Bienaimé (Director), Carl Gordon (Director), Carl Gordon (Director), Julius Knowles (Director), Jennifer Lachey (Insider), Charles Newton (Director), Keith Regnante (CFO), and Alpna Seth (Director). Learn More on Keros Therapeutics' active insiders.
Are insiders buying or selling shares of Keros Therapeutics?: During the last year, Keros Therapeutics insiders bought shares 2 times. They purchased a total of 2,000 shares worth more than $21,890.00. During the last year, insiders at the sold shares 6 times. They sold a total of 10,185,020 shares worth more than $180,724,555.75. The most recent insider tranaction occured on June, 15th when Director Jean Jacques Bienaime bought 1,000 shares worth more than $10,190.00. Insiders at Keros Therapeutics own 12.6% of the company. Learn More about insider trades at Keros Therapeutics.
Information on this page was last updated on 6/15/2026.

Jean-Jacques Bienaimé Insider Trading History at Keros Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/15/2026	Buy	1,000	$10.19	$10,190.00	17,592
4/15/2026	Buy	1,000	$11.70	$11,700.00	8,450

Jean-Jacques Bienaimé Buying and Selling Activity at Keros Therapeutics

Keros Therapeutics Company Overview

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $10.59

$10.37

$10.76

50 Day Range

MA: $10.90

$9.91

$12.07

2 Week Range

Now: $10.59

$9.69

$22.55

Volume

56,160 shs

Average Volume

362,882 shs

Market Capitalization

$209.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97